Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

Wang, Lei‐Yun; Cui, Jiajia; Guo, Ao-Xiang

doi:10.2147/ott.s136579

Cited by 14 publications

(8 citation statements)

References 99 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most lung cancer is first detected when the volume of the mass reaches very large. Due to extensive local spread and distant metastasis, about 60% of lung cancer patients are incurable 3. Therefore, there is an urgent clinical need to find novel biomarkers as new targets for lung cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

<p>Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis</p>

Wang¹,

Yang²,

Lei³

et al. 2019

CMAR

View full text Add to dashboard Cite

Purpose Keratin 17 (KRT17) is a 48 KDa type I intermediate filament, which is mainly expressed in epithelial basal cells. KRT17 has been shown to be overexpressed in many malignant tumors and play an important role in the occurrence and development of tumors. Therefore, this study explored the role and underlying mechanism of KRT17 in non-small cell lung cancers (NSCLC). Methods KRT17 expression and its correlations with clinicopathological factors were examined in lung cancer tissues by immunohistochemistry. The prognosis value of KRT17 in NSCLCs was retrieved from The Cancer Genome Atlas (TCGA) online databases. The expression level of KRT17 was increased or decreased by KRT17 gene transfection or small RNA interference in lung cancer cells, respectively. Further, proliferation and invasiveness of lung cancer cells were determined by cell proliferation and invasion assays, respectively. Finally, expression levels of proteins related to Wnt signaling pathways and epithelial mesenchymal transition (EMT) were detected by Western blot. Results The expression level of KRT17 in NSCLCs was significantly higher than normal lung tissues. High expression of KRT17 predicted poor prognosis of patients with NSCLCs, especially lung adenocarcinomas, and was correlated with poor differentiation and lymphatic metastasis. Overexpression of KRT17 enhanced, while KRT17 knockdown inhibited, the proliferation and invasiveness of lung cancer cells. Overexpression of KRT17 up-regulated β-catenin activity and levels of Wnt target genes, such as cyclin D1, c-Myc, and MMP7. Moreover, KRT17 promoted EMT by up-regulating Vimentin, MMP-9, and Snail expression and down-regulating E-cadherin expression. Conclusion Overexpression of KRT17 is common in NSCLCs and indicates poor prognosis. Overexpression of KRT17 enhances the proliferation and invasiveness of NSCLC cells by activating the Wnt signaling pathway and EMT process. KRT17 is a potential indicator of NSCLC progression and poor survival.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis</p>

Wang¹,

Yang²,

Lei³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…For the treatment of lung cancer, surgery, chemotherapy and radiotherapy are still the primary choice in the clinic. In recent years, immunotherapy and targeted therapy are gradually developed and bring great potential for these patients, such as cytokine-induced killer cells [3,4].…”

Section: Introductionmentioning

confidence: 99%

The value of Cone-Beam CT-guided radiofrequency ablation in the treatment of pulmonary malignancies (≤3 cm)

Xiang

Wang

et al. 2019

Bioscience Reports

View full text Add to dashboard Cite

The aim of this study is to explore the safety and efficacy of Cone-Beam computed tomography (CBCT) guided radiofrequency ablation (RFA) in the treatment of pulmonary malignancies. Thirty-one patients with pulmonary malignant tumors (≤3 cm in diameter) were enrolled to this study. Total 43 CBCT guided RFA treatments were performed, including 7 patients undergoing multiple treatments. The target tumor puncture success rate, tumor remission rate, postoperative cumulative survival rate, tumor-free survival rate and complication rate were analyzed. All 43 CBCT guided RFA procedures successfully punctured the target tumors. Complications included five cases of pneumothorax and three cases of hemoptysis. For the 31 patients who underwent CBCT guided RFA, the 1- and 2-year cumulative survival rates were 80.6 and 54.8%, respectively. The 1- and 2-year disease-free survival rates were 54.8 and 32.3%, respectively. The 1-, 3- and 6-month remission rates were 78.4, 68.7 and 63.3%, respectively. The average cumulative radiation dose and average effective radiation dose were 194.62 ± 105.51 mGy and 5.41 ± 3.45 mSv, respectively. CBCT help to shorten the operation time, reduce the unnecessary interventions and also reduce the incidence of complications. CBCT guided RFA is one safe and efficacious treatment for pulmonary malignancies.

show abstract

“…66 In addition, cross trial comparisons show higher rates of discontinuation with afatinib (28-53.5% in LUX-Lung 3 and LUX-Lung 6) compared with gefitinib or erlotinib (6-21% in IPASS, OPTIMAL, and EURTAC). [66][67][68][69] In the randomized head-to-head LUX-Lung 7 trial against gefitinib, afatinib failed to find any OS benefit and there was a meager 3 days' benefit in median PFS (11.0 months for the afatinib group vs. 10.9 months for the gefitinib arm; HR ¼ 0.73, p ¼ 0.017). 70 On the other hand, dacomitinib was approved by the FDA in 2018 for the first-line treatment of patients with NSCLC harboring an exon 19 deletion or L858R mutation in EGFR.…”

Section: Second-generation Egfr Tkismentioning

confidence: 99%

Targeted Therapy for Non-Small Cell Lung Cancer

Noor

Cummings

Johnson

et al. 2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic profiling has allowed for the characterization of its molecular subtypes. This has increased the ability to deliver “personalized medicines” by tailoring therapies to target driver mutations in a patient's cancer. The development of targeted therapies for non-small cell lung cancer (NSCLC) has helped define the era of precision medicine throughout oncology. This article aims to contextualize recent research and provide an updated summary of targeted therapies available for patients with NSCLC. With practitioners and clinical researchers in mind, we note standard of care therapies, important approvals, practice guidelines, and treatments in development. The first section discusses mutations in the epidermal growth factor receptor (EGFR) gene, and the second section examines rearrangements in the anaplastic lymphoma kinase (ALK) and ROS1 fusions. Finally, we explore the rarer molecular alterations in BRAF, RET, MET, HER2, and KRAS. Given the many available therapies, it is important to understand the molecular alterations in NSCLC, and how to target them.

show abstract

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

Cited by 14 publications

References 99 publications

<p>Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis</p>

<p>Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis</p>

The value of Cone-Beam CT-guided radiofrequency ablation in the treatment of pulmonary malignancies (≤3 cm)

Targeted Therapy for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About